PMEF
RPRX icon

Point72 Middle East FZE’s Royalty Pharma RPRX Stock Holding History

Point72 Middle East FZE’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-113,121
Closed -$3.18M – 1075
2023
Q4 		$3.18M Buy
113,121
+73,602
+186% +$2.02M 0.09% 284
2023
Q3 		$1.07M Buy
39,519
+1,460
+4% +$43.4K 0.04% 551
2023
Q2 		$1.17M Buy
38,059
+12,016
+46% +$407K 0.03% 540
2023
Q1 		$938K Buy
+26,043
New +$966K 0.03% 522

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Middle East FZE's RPRX Position: Q1 2024 in Review

Point72 Middle East FZE sold out of Royalty Pharma (RPRX) in Q1 2024, closing a stake of 113,121 shares — an estimated $3.18M sold.

Point72 Middle East FZE first reported a position in RPRX in Q1 2023 and held it in 4 quarters. The position peaked at $3.18M in Q4 2023. 378 funds tracked by Wall St. Rank hold RPRX as of Q1 2024.

  • Point72 Middle East FZE reported no remaining Royalty Pharma position as of Q1 2024 after selling out during the quarter.
  • Point72 Middle East FZE sold 113,121 Royalty Pharma shares in Q1 2024, an estimated $3.18M.
  • Point72 Middle East FZE first reported a position in Royalty Pharma in Q1 2023 and held it in 4 quarters.
  • Point72 Middle East FZE's Royalty Pharma position peaked at $3.18M in Q4 2023.
  • 378 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2024.

Based on Point72 Middle East FZE's 13F filing for Q1 2024.